Evexia Wealth LLC Acquires 235 Shares of Eli Lilly and Company (NYSE:LLY)

Evexia Wealth LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.8% during the fourth quarter, Holdings Channel reports. The fund owned 8,715 shares of the company’s stock after purchasing an additional 235 shares during the period. Eli Lilly and Company makes up about 2.2% of Evexia Wealth LLC’s holdings, making the stock its 20th biggest holding. Evexia Wealth LLC’s holdings in Eli Lilly and Company were worth $5,080,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in LLY. International Assets Investment Management LLC grew its stake in shares of Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after buying an additional 7,330,815 shares during the last quarter. Sapient Capital LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $682,139,000. J.P. Morgan Private Wealth Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth about $435,736,000. Vanguard Group Inc. boosted its stake in Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Eli Lilly and Company by 24.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after purchasing an additional 645,473 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LLY. Morgan Stanley upped their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. BMO Capital Markets increased their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Barclays boosted their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. increased their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Finally, DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research report on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $11.09 on Tuesday, hitting $777.77. 2,842,407 shares of the company’s stock were exchanged, compared to its average volume of 3,088,457. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78. The company has a 50-day simple moving average of $761.22 and a 200-day simple moving average of $674.88. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The stock has a market capitalization of $739.20 billion, a PE ratio of 114.55, a PEG ratio of 1.45 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the business earned $1.62 earnings per share. Eli Lilly and Company’s quarterly revenue was up 26.0% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.